Trials / Withdrawn
WithdrawnNCT02427893
Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
An Exploratory Study of the Immunological Effects of Vemurafenib and Cobimetinib, Administered Alone and in Combination, in Subjects With Advanced BRAF V600E/K Mutant Melanoma
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial explores the immunologic effects of vemurafenib (BRAF inhibitor) and cobimetinib (MEK inhibitor), administered alone and in combination, to patients with advanced BRAF V600E/K mutant melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cobimetinib | A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway. |
| DRUG | Vemurafenib | A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2016-11-01
- Completion
- 2016-11-01
- First posted
- 2015-04-28
- Last updated
- 2016-11-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02427893. Inclusion in this directory is not an endorsement.